Precision oncology therapies account for nearly half of new cancer drug approvals since 1998

  • Post author:
  • Post category:uncategorized

Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.